Published in J Neuroimmunol on October 01, 1997
Identification of virulence mutants of the fungal pathogen Cryptococcus neoformans using signature-tagged mutagenesis. Genetics (2001) 1.38
Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection. Infect Immun (1999) 1.08
A new azole derivative of 1,4-benzothiazine increases the antifungal mechanisms of natural effector cells. Antimicrob Agents Chemother (1999) 0.86
Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol (1990) 4.37
Selective immortalization of murine macrophages from fresh bone marrow by a raf/myc recombinant murine retrovirus. Nature (1986) 2.64
Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. Infect Immun (1991) 2.46
Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med (1996) 2.41
Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. J Exp Med (1992) 2.37
CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. J Immunol (1993) 2.30
Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur J Immunol (1993) 2.05
An immortalized cell line expresses properties of activated microglial cells. J Neurosci Res (1992) 1.87
Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun (1986) 1.86
An immunoregulatory role for neutrophils in CD4+ T helper subset selection in mice with candidiasis. J Immunol (1997) 1.76
IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol (2010) 1.76
IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J Immunol (1994) 1.75
Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J Immunol (1994) 1.72
Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun (1996) 1.71
A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice. Infect Immun (1994) 1.68
Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol (1997) 1.68
Interleukin-12 in infectious diseases. Clin Microbiol Rev (1997) 1.63
Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun (1997) 1.61
Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice. Infect Immun (1989) 1.56
Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun (1996) 1.53
Rapid methods to extract DNA and RNA from Cryptococcus neoformans. FEMS Yeast Res (2001) 1.52
Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species. J Clin Microbiol (2002) 1.51
Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans infection. Am J Respir Cell Mol Biol (1994) 1.51
In vitro production of tumor necrosis factor by murine splenic macrophages stimulated with mannoprotein constituents of Candida albicans cell wall. Cell Immunol (1991) 1.49
T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol (2000) 1.48
The A-domain and the thrombospondin-related motif of Plasmodium falciparum TRAP are implicated in the invasion process of mosquito salivary glands. EMBO J (1999) 1.47
Effect of corticosteroid treatment on interleukin-1 and tumour necrosis factor secretion by monocytes from subjects with asthma. Clin Exp Allergy (1992) 1.46
Heterogeneity of hematopoietic cells immortalized by v-myc/v-raf recombinant retrovirus infection of bone marrow or fetal liver. J Natl Cancer Inst (1989) 1.44
Correlation between in vivo and in vitro studies of modulation of resistance to experimental Candida albicans infection by cyclophosphamide in mice. Infect Immun (1983) 1.43
T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. J Infect Dis (1995) 1.41
Interleukin 18 restores defective Th1 immunity to Candida albicans in caspase 1-deficient mice. Infect Immun (2000) 1.39
Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis (1998) 1.39
Cell wall components of Candida albicans as immunomodulators: induction of natural killer and macrophage-mediated peritoneal cell cytotoxicity in mice by mannoprotein and glucan fractions. J Gen Microbiol (1988) 1.38
Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol (1994) 1.37
Two conserved amino acid motifs mediate protein targeting to the micronemes of the apicomplexan parasite Toxoplasma gondii. Mol Cell Biol (2000) 1.36
Interleukin-12 but not interferon-gamma production correlates with induction of T helper type-1 phenotype in murine candidiasis. Eur J Immunol (1994) 1.33
In vitro natural cell-mediated cytotoxicity against Candida albicans: macrophage precursors as effector cells. J Immunol (1985) 1.30
T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice. J Immunol (1990) 1.29
Role of nitric oxide and melanogenesis in the accomplishment of anticryptococcal activity by the BV-2 microglial cell line. J Neuroimmunol (1995) 1.28
S100B expression in and effects on microglia. Glia (2001) 1.28
Antifungal type 1 responses are upregulated in IL-10-deficient mice. Microbes Infect (1999) 1.27
Interleukin-4 and -10 exacerbate candidiasis in mice. Eur J Immunol (1995) 1.27
Serodiagnosis of infectious diseases with antigen microarrays. J Appl Microbiol (2004) 1.25
Experimental model of type IV Streptococcus agalactiae (group B streptococcus) infection in mice with early development of septic arthritis. Infect Immun (1990) 1.25
Immunosuppressive effect of cyclosporin A on resistance to systemic infection with Candida albicans. J Med Microbiol (1989) 1.25
Protective immunity induced by low-virulence Candida albicans: cytokine production in the development of the anti-infectious state. Cell Immunol (1989) 1.21
Natural cell-mediated cytotoxicity against Candida albicans induced by cyclophosphamide: nature of the in vitro cytotoxic effector. Infect Immun (1983) 1.20
Gamma interferon modifies CD4+ subset expression in murine candidiasis. Infect Immun (1992) 1.19
A comparison of experimental pathogenicity of Candida species in cyclophosphamide-immunodepressed mice. Sabouraudia (1984) 1.19
Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis (1999) 1.19
Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J Infect Dis (1994) 1.19
Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis (1997) 1.19
CD4+ T-helper-cell responses in mice with low-level Candida albicans infection. Infect Immun (1996) 1.18
Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. Antimicrob Agents Chemother (1985) 1.18
Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect Immun (1998) 1.16
Increase of mouse resistance to Candida albicans infection by thymosin alpha 1. Infect Immun (1982) 1.13
A TH1-TH2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol (1995) 1.12
IFN-gamma is required for IL-12 responsiveness in mice with Candida albicans infection. J Immunol (1998) 1.12
Augmentation of GG2EE macrophage cell line-mediated anti-Candida activity by gamma interferon, tumor necrosis factor, and interleukin-1. Infect Immun (1990) 1.10
[Use of potassium chloride hypertonic saline solution (3M KC1) for extraction of soluble antigens from Candida albicans]. Ann Sclavo (1976) 1.10
Tryptophan catabolism in IDO+ plasmacytoid dendritic cells. Curr Drug Metab (2007) 1.10
Experimental model of intracerebral infection with Cryptococcus neoformans: roles of phagocytes and opsonization. Infect Immun (1992) 1.10
In-vitro killing of Candida species by murine immunoeffectors and its relationship to the experimental pathogenicity. Sabouraudia (1985) 1.09
IL-10 is required for development of protective Th1 responses in IL-12-deficient mice upon Candida albicans infection. J Immunol (1998) 1.09
Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans. Infect Immun (2001) 1.08
Azole derivatives of 1,4-benzothiazine as antifungal agents. Bioorg Med Chem (1998) 1.08
Course of primary candidiasis in T cell-depleted mice infected with attenuated variant cells. J Infect Dis (1992) 1.07
Defective co-stimulation and impaired Th1 development in tumor necrosis factor/lymphotoxin-alpha double-deficient mice infected with Candida albicans. Int Immunol (1998) 1.07
Intracerebral transfer of an in vitro established microglial cell line: local induction of a protective state against lethal challenge with Candida albicans. J Neuroimmunol (1991) 1.07
Early induction of interleukin-12 by human monocytes exposed to Cryptococcus neoformans mannoproteins. Infect Immun (2000) 1.06
The contribution of PARs to inflammation and immunity to fungi. Mucosal Immunol (2008) 1.06
Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pulmonary aspergillosis. J Infect Dis (2001) 1.06
Severity of group B streptococcal arthritis is correlated with beta-hemolysin expression. J Infect Dis (2000) 1.05
Inhibition of candidacidal activity of polymorphonuclear cells by alveolar macrophage-derived factor from lung cancer patients. Am Rev Respir Dis (1993) 1.05